Novartis raises forecasts for three key growth products
Novartis has raised its peak sales expectations for three key growth products – Kesimpta, Scemblix, and Leqvio – by around $4 billion as it targets 5% annual revenue growth between 2026 and 2031.
"Novartis has a strong track record of sales growth and core margin expansion, and in 2026 we expect to grow through the largest loss-of-exclusivity impact in our history," said chief executive Vas Narasimhan, referring to patent expiries for big-selling brands like heart failure therapy Entresto (sacubitril/valsartan) and anaemia therapy Promacta (eltrombopag).
The updated forecast now puts peak sales of multiple sclerosis therapy Kesimpta (ofatumumab) at $8 billion rather than $6 billion, while expectations for blood cancer therapy Scemblix (asciminib) and twice-yearly cholesterol-reducer Leqvio (inclisiran) have both swelled by $1 billion to $5 billion each.
The optimistic outlook follows prior upgraded sales targets for breast cancer therapy Kisqali (ribociclib) and oral BTK inhibitor Rhapsido (remibrutinib) for immunology and inflammation (I&I) conditions – to $10 billion and $4 billion, respectively – and means that Novartis now has nine in-market assets with $3 billion to $10 billion peak sales potential.
The optimistic assessment comes despite a string of late-stage pipeline setbacks in recent months, including a failed phase 3 trial for delpacibart etedesiran (del-desiran) - one of three antibody-oligonucleotide conjugates (AOCs) added through its $12 billion takeover of Avidity Biosciences – in myotonic dystrophy type 1 (DM1).
Novartis took a $1.9 billion impairment charge in the third quarter of this year connected to the Avidity acquisition. Meanwhile, other recent challenges include a highly anticipated cardiovascular outcomes trial for Lp(a)-targeted pelacarsen, which was a bust, and the suspension of clinical trials of its experimental CAR-T cell therapy, rapcabtagene autoleucel (rap-cel), for autoimmune diseases.
In its update, Novartis shrugged off those issues, pointing to a pipeline of what it claims are 30-plus "high-value" assets, including "10 in late-stage development with multibillion-dollar peak sales guidance."
Those include recently filed myelofibrosis treatment pelabresib, systemic lupus erythematosus candidate ianalumab, and two other Avidity AOCs, delpacibart braxlosiran (del-brax) for facioscapulohumeral muscular dystrophy (FSHD) and delpacibart zotadirsen (del-zota) for Duchenne muscular dystrophy (DMD) amenable to exon 44 skipping.
"Alongside our late-stage programs advancing through phase 3, our full phase 1 and 2 pipeline gives us further confidence that we can sustain mid-single-digit growth over the longer term," said Narasimhan.
Photo by mostafa meraji on Unsplash
